Diabetes franchise

In 1Q17, AstraZeneca (AZN) witnessed a 1% year-over-year (or YoY) drop in revenues earned by its diabetes portfolio. Intense pricing and competitive pressures resulted in a 7% YoY drop in the company’s diabetes franchise sales in the US market in 1Q17.

In Europe, the company witnessed ~1% growth in diabetes product sales despite declining demand for Onglyza. This is mainly attributed to the increasing adoption of Farxiga in Europe.

Farxiga Expected to Drive AstraZeneca’s Performance in Diabetes SegmentFarxiga’s growth trends

In 1Q17, AstraZeneca’s leading sodium-glucose co-transporter 2 (or SGLT2) therapy for type-2 diabetes, Farxiga, reported revenues close to $270 million, which is YoY growth of ~25% on a constant currency basis.

In the US, the drug reported sales close to $96 million, which is YoY growth of only 2%, due to the negative impact of restricted managed care access, ongoing affordability programs, and changing inventory levels. To learn more about Farxiga, please read What to Expect from AstraZeneca’s Farxiga in 2017.

AstraZeneca, however, is confident that the SGLT2 class of drugs could gradually capture the market of other type-2 diabetes class of drugs, specifically Dipeptidyl peptidase-4 (or DPP4) inhibitors such as Merck’s (MRK) Januvia and Janumet.

As physicians are becoming more confident prescribing SGLT2 drugs, they are being prescribed at an earlier stage of the disease, just after metformin and prior to DPP-4 inhibitors. Physicians are also combining SGLT2 inhibitors with other type-2 diabetes therapies at earlier stages of diabetes.

SGLT-2 inhibitors such as Farxiga, Johnson & Johnson’s (JNJ) Invokana, Boehringer Ingelheim and Eli Lilly’s (LLY) Jardiance, and others are expected to benefit from positive results of CVD-REAL, the first large study based on real-world evidence.

This study has demonstrated that type-2 diabetes patients treated with SGLT2 inhibitors witnessed a 51% reduction in mortality and a 39% drop in hospitalizations due to heart failure compared to patients treated with other classes of drugs.

This ongoing study, comprising more than 300,000 patients around the world, is expected to boost the uptake of Farxiga in 2017. This, in turn, would have a positive impact on AstraZeneca stock as well as the Vanguard FTSE All-World ex-US ETF (VEU). AstraZeneca makes up about 0.18% of VEU’s total portfolio holdings.

In the next article, we’ll discuss major trends for AstraZeneca’s Farxiga in international markets.

Latest articles

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let's take a closer look at each.

Walt Disney’s (DIS) latest movie, Toy Story 4, has reportedly broken records in the opening weekend with $118 million in sales. However, the opening weekend collection was behind analysts’ expectations of at least $150 million in the first weekend.

24 Jun

Will Home Depot’s Upward Momentum to Continue?

WRITTEN BY Rajiv Nanjapla

As of June 21, Home Depot (HD) was trading at $209.39, which implies a rise of 9.7% since the announcement of its first-quarter earnings on May 21. Also, the company was trading at a premium of 32.4% from its 52-week low of $158.09 and a discount of 2.8% from its 52-week high of $215.43.

On June 21, Aurora Cannabis (ACB) made an announcement that indicated that it will move towards higher margin vape products. In addition, the company also believes concentrates and edibles will command higher margins. In anticipation of this development, the company announced the expansion of its facility to capitalize on growth related to these segments.

Shares of Mondelēz International (MDLZ) are scaling new heights thanks to its stellar gains so far this year. Mondelēz stock is up 38.0% on a YTD (year-to-date) basis, and it closed at $55.25—just a shade lower than its 52-week high of $55.71—on June 21.

24 Jun

How Long Will Facebook's Libra Fuel Bitcoin Rally?

WRITTEN BY Mayur Sontakke, CFA, FRM

Ever since the news about Facebook’s (FB) cryptocurrency project broke, Bitcoin has rallied on the hope that Facebook’s entry in the space will help make cryptocurrencies mainstream. Facebook’s cryptocurrency will be called Libra and will be governed by an association with 28 founding members across industries.